NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system
S Chen, Y Gu, H Yu, X Chen, T Cao, L Hu… - European journal of …, 2021 - Springer
Purpose In this paper, we aimed to evaluate the positron emission tomography (PET)
performance of, to the best of our knowledge, the third commercially available whole-body …
performance of, to the best of our knowledge, the third commercially available whole-body …
Unpaired whole-body MR to CT synthesis with correlation coefficient constrained adversarial learning
MR to CT image synthesis plays an important role in medical image analysis, and its
applications included, but not limited to PET-MR attenuation correction and MR only radiation …
applications included, but not limited to PET-MR attenuation correction and MR only radiation …
The state of instrumentation for combined positron emission tomography and magnetic resonance imaging
P Vaska, T Cao - Seminars in nuclear medicine, 2013 - Elsevier
Efforts at developing instrumentation for combined positron emission tomography and magnetic
resonance imaging have gained considerable momentum in recent years, propelled in …
resonance imaging have gained considerable momentum in recent years, propelled in …
[HTML][HTML] Validation of MR-based attenuation correction of a newly released whole-body simultaneous PET/MR system
G Liu, T Cao, L Hu, J Zheng, L Pang, P Hu… - BioMed research …, 2019 - hindawi.com
The aim of this study was to validate quantitative performance of a newly released simultaneous
positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner, by …
positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner, by …
Optical flow-based vascular respiratory motion compensation
K Yang, Z Zhang, M Li, T Cao… - IEEE Robotics and …, 2023 - ieeexplore.ieee.org
This letter develops a new vascular respiratory motion compensation algorithm, Motion-Related
Compensation (MRC), to conduct vascular respiratory motion compensation by …
Compensation (MRC), to conduct vascular respiratory motion compensation by …
[HTML][HTML] PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
…, Y Peng, X Yu, Y Gao, B Yuan, Q Zhu, T Cao… - Journal of Experimental …, 2018 - Springer
Background The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved
for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP …
for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP …
UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated …
…, Y Liu, Y Liu, Y Peng, B Yuan, Y Fu, X Qi, Q Zhu, T Cao… - Cancer Letters, 2021 - Elsevier
The UHRF1 and CDC6, oncogenes play critical roles in therapeutic resistance. In the
present study, we found that UHRF1 mediates androgen receptor (AR)-regulated CDC6 …
present study, we found that UHRF1 mediates androgen receptor (AR)-regulated CDC6 …
[HTML][HTML] Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition
…, L Yin, Y Peng, Y Peng, Y Gao, B Yuan, Q Zhu, T Cao… - Oncogene, 2019 - nature.com
Ionizing radiation (IR) is a conventional cancer therapeutic, to which cancer cells develop
radioresistance with exposure. The residual cancer cells after radiation treatment also have …
radioresistance with exposure. The residual cancer cells after radiation treatment also have …
[HTML][HTML] FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness
…, Y Liu, X Yu, L Yin, Y Peng, Y Gao, Q Zhu, T Cao… - Cell Death & …, 2018 - nature.com
Therapy-induced expansion of cancer stem cells (CSCs) has been identified as one of the
most critical factors contributing to therapeutic resistance, but the mechanisms of this …
most critical factors contributing to therapeutic resistance, but the mechanisms of this …
[HTML][HTML] USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis
…, Y Liu, Y Gao, B Yuan, X Qi, Y Fu, Q Zhu, T Cao… - Journal of Experimental …, 2019 - Springer
Background The deubiquitinase USP7 has been identified as an oncogene with key roles in
tumorigenesis and therapeutic resistance for a series of cancer types. Recently small …
tumorigenesis and therapeutic resistance for a series of cancer types. Recently small …